A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTerpath-002)

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Locations

Memorial Hospital Central
Memorial Hospital North

Principal Investigator
Photograph of Robert Hoyer

Robert Hoyer

Study ID

Protocol Number: 23-1996

More information available at ClinicalTrials.gov: NCT06077760

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers